Targeting the MET gene for the treatment of non-small-cell lung cancer.
Crit Rev Oncol Hematol
; 89(2): 284-99, 2014 Feb.
Article
em En
| MEDLINE
| ID: mdl-24355409
Palavras-chave
AEs; ALK; EGFR; FISH; HGF; HGFR; HR; Hepatocyte growth factor; IHC; ITT; Kinase inhibitors; MET; MTD; NSCLC; OS; PFS; PSI; RTKs; SCLC; Sema; Targeted therapies; adverse events; anaplastic lymphoma kinase; epidermal growth factor receptor; fluorescent in situ hybridization; hazard ratio; hepatocyte growth factor; hepatocyte growth factor receptor; immunohistochemistry; intent to treat; maximum tolerated dose; non small cell lung cancer; overall survival; plexin-semaphorin-integrin; progression free survival; semaphorin; small cell lung cancer; tyrosine kinase receptors
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Proteínas Proto-Oncogênicas c-met
/
Inibidores de Proteínas Quinases
/
Terapia de Alvo Molecular
/
Receptores ErbB
/
Neoplasias Pulmonares
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Crit Rev Oncol Hematol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2014
Tipo de documento:
Article